Terumo Corporation logo

Terumo Corporation

4543.T

JPXHealthcareMedical - Instruments & Supplies

Latest quote

¥2,595.5

+¥26.50 · +1.03%

Aug 24, 3:30 PM JST

4543.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
JP
CEO
Hikaru Samejima
Listed since
Jun 20, 1982
Employees
31,185

Market position

Day range

Current ¥2,595.5

52-week range

Current ¥2,595.5

Open
¥2,578.5
Previous close
¥2,569
Volume
3.08M
0.57× average
Average volume
5.36M
Average daily volume
Market cap
3.83T JPY
Beta
0.23
Market reference 1
50-day average
¥2,310.22
+12.35% above average
200-day average
¥2,220.43
+16.89% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.21T JPY
EV / EBITDA
11.59×
Earnings yield
4.37%
Free cash flow yield
4.68%

Profitability & efficiency

Return on equity
8.58%
Return on assets
5.88%
Return on invested capital
6.87%

Financial health

Current ratio
1.59×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends57%40%23%7%Gross margin, FY2022: 49.59%Gross margin, FY2023: 48.02%Gross margin, FY2024: 49.27%Gross margin, FY2025: 51.42%Gross margin, FY2026: 52.54%Operating margin, FY2022: 16.80%Operating margin, FY2023: 14.31%Operating margin, FY2024: 14.56%Operating margin, FY2025: 17.28%Operating margin, FY2026: 16.32%Net margin, FY2022: 12.63%Net margin, FY2023: 10.89%Net margin, FY2024: 11.54%Net margin, FY2025: 11.29%Net margin, FY2026: 12.01%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 49.59%. Gross margin FY2023 48.02%. Gross margin FY2024 49.27%. Gross margin FY2025 51.42%. Gross margin FY2026 52.54%. Operating margin FY2022 16.80%. Operating margin FY2023 14.31%. Operating margin FY2024 14.56%. Operating margin FY2025 17.28%. Operating margin FY2026 16.32%. Net margin FY2022 12.63%. Net margin FY2023 10.89%. Net margin FY2024 11.54%. Net margin FY2025 11.29%. Net margin FY2026 12.01%.

Income trends

Revenue

1.13T JPY+9.24%

Operating income

184.74B JPY+3.19%

Net income

135.91B JPY+16.19%
Income trends across reported periods1.24T JPY818.96B JPY401.73B JPY−15.49B JPYRevenue, FY2022: 703.3B JPYRevenue, FY2023: 820.21B JPYRevenue, FY2024: 921.86B JPYRevenue, FY2025: 1.04T JPYRevenue, FY2026: 1.13T JPYOperating income, FY2022: 118.12B JPYOperating income, FY2023: 117.33B JPYOperating income, FY2024: 134.2B JPYOperating income, FY2025: 179.02B JPYOperating income, FY2026: 184.74B JPYNet income, FY2022: 88.81B JPYNet income, FY2023: 89.33B JPYNet income, FY2024: 106.37B JPYNet income, FY2025: 116.98B JPYNet income, FY2026: 135.91B JPYFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 703.3B JPY. Revenue FY2023 820.21B JPY. Revenue FY2024 921.86B JPY. Revenue FY2025 1.04T JPY. Revenue FY2026 1.13T JPY. Operating income FY2022 118.12B JPY. Operating income FY2023 117.33B JPY. Operating income FY2024 134.2B JPY. Operating income FY2025 179.02B JPY. Operating income FY2026 184.74B JPY. Net income FY2022 88.81B JPY. Net income FY2023 89.33B JPY. Net income FY2024 106.37B JPY. Net income FY2025 116.98B JPY. Net income FY2026 135.91B JPY.
Metric (JPY)FY2026FY2025FY2024FY2023FY2022
Revenue1.13T JPY1.04T JPY921.86B JPY820.21B JPY703.3B JPY
Cost of goods sold537.2B JPY503.39B JPY467.69B JPY426.37B JPY354.56B JPY
Gross profit594.68B JPY532.78B JPY454.17B JPY393.84B JPY348.75B JPY
Research and development74.22B JPY69.06B JPY61.58B JPY51.84B JPY
Selling, general, and administrative409.94B JPY279.53B JPY250.92B JPY214.92B JPY178.79B JPY
Operating expenses409.94B JPY353.76B JPY319.98B JPY276.5B JPY230.63B JPY
Interest income6.25B JPY3.36B JPY2.41B JPY1.47B JPY510M JPY
Interest expense3.29B JPY2.02B JPY2.07B JPY2.23B JPY1.64B JPY
Depreciation and amortization95.38B JPY85.45B JPY76.75B JPY70.24B JPY58.88B JPY
Operating income184.74B JPY179.02B JPY134.2B JPY117.33B JPY118.12B JPY
Net income135.91B JPY116.98B JPY106.37B JPY89.33B JPY88.81B JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+12.44%
11 comparable reports
Latest EPS result
47.74
Estimate 25.18 · Beat by 89.59%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates50.5637.2423.9110.58Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 23.96, estimate 20.59, surprise +16.37%, Beat. Q2 2025, reported May 14, 2025: actual 12.45, estimate 20.75, surprise -40.00%, Miss. Q3 2025, reported Aug 7, 2025: actual 28.37, estimate 24.4, surprise +16.27%, Beat. Q4 2025, reported Nov 12, 2025: actual 23.76, estimate 24.5, surprise -3.02%, Miss. Q1 2026, reported Feb 13, 2026: actual 21.65, estimate 22.07, surprise -1.90%, Miss. Q2 2026, reported May 15, 2026: actual 17.89, estimate 15.02, surprise +19.11%, Beat. Q3 2026, reported Aug 7, 2026: actual 47.74, estimate 25.18, surprise +89.59%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 26.98, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates324.28B297.05B269.82B242.59BQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 255.06B JPY, estimate 260.14B JPY, surprise -1.95%, Miss. Q2 2025, reported May 14, 2025: actual 263.94B JPY, estimate 259.14B JPY, surprise +1.85%, Beat. Q3 2025, reported Aug 7, 2025: actual 259.97B JPY, estimate 262.34B JPY, surprise -0.90%, Miss. Q4 2025, reported Nov 12, 2025: actual 287.35B JPY, estimate 264.02B JPY, surprise +8.84%, Beat. Q1 2026, reported Feb 13, 2026: actual 290.04B JPY, estimate 286.86B JPY, surprise +1.11%, Beat. Q2 2026, reported May 15, 2026: actual 300.66B JPY, estimate 290.13B JPY, surprise +3.63%, Beat. Q3 2026, reported Aug 7, 2026: actual 311.81B JPY, estimate 295.46B JPY, surprise +5.53%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 307.4B JPY, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥28.00

2025 complete year+86.7% since 2021

2026 partial: ¥15.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Sep 29, 2026

¥18.00

Semi-Annual

Record Sep 30, 2026 · Payment Sep 29, 2026

DividendUpcoming

Ex-dividend Mar 30, 2027

¥18.00

Semi-Annual

Record Mar 31, 2027 · Payment Mar 30, 2027

Dividend

Ex-dividend Mar 30, 2026

¥15.00

Semi-Annual

Record Mar 31, 2026 · Payment Jun 29, 2026

Dividend

Ex-dividend Sep 29, 2025

¥15.00

Semi-Annual

Record Sep 30, 2025 · Payment Dec 2, 2025

Dividend

Ex-dividend Mar 28, 2025

¥13.00

Semi-Annual

Record Mar 31, 2025 · Payment Jun 25, 2025

Dividend

Ex-dividend Sep 27, 2024

¥13.00

Semi-Annual

Record Sep 30, 2024 · Payment Dec 3, 2024

4543.T peers

ETFs holding 4543.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 4543.T

research.disclaimer